GlassScriptPhysician profile
Nikhil Bhayani
NPI 1497950554
$56,682.39
in general payments reported to CMS, 2019-2025
27 companies · $15K in 2025
The $15K reported for 2025 was more than what 95% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $878 · 2021: $572 · 2022: $1,607 · 2023: $14K · 2024: $24K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $10K · Food and Beverage: $7,386 · Travel and Lodging: $4,232 · Education: $34.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,850.13 |
| Consulting Fee | $10,330.00 |
| Food and Beverage | $7,385.85 |
| Travel and Lodging | $4,231.91 |
| Education | $34.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $20,439.40 | 2019-2025 | Vibativ, Caldolor, Sancuso |
| Paratek Pharmaceuticals, INC. | $18,470.19 | 2019-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $7,043.25 | 2019-2025 | Kimyrsa, Rezzayo, Vabomere |
| Viiv Healthcare Company | $4,590.77 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Ferring Pharmaceuticals INC. | $1,480.63 | 2023 | Rebyota |
| Gilead Sciences, INC. | $1,004.16 | 2019-2025 | Biktarvy, Veklury |
| Merck Sharp & Dohme LLC | $694.67 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Fisher Scientific Company L.L.C. | $563.65 | 2019-2022 | |
| Abbvie INC. | $339.19 | 2021-2025 | Avycaz |
| Insmed, INC. | $329.01 | 2020-2025 | Arikayce |
| Shionogi INC | $295.98 | 2020-2025 | Fetroja |
| La Jolla Pharmaceutical Company | $272.69 | 2021-2025 | Zevtera |
| Abbott Laboratories | $249.63 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $153.30 | 2019-2020 | |
| Cepheid | $123.00 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $116.58 | 2022 | |
| Aimmune Therapeutics, INC. | $99.33 | 2024-2025 | Vowst |
| Janssen Biotech, INC. | $95.59 | 2019-2023 | Symtuza |
| Janssen Products, LP | $65.00 | 2021 | |
| Theratechnologies INC. | $57.23 | 2019-2021 | |
| Philips North America LLC | $39.04 | 2024-2025 | Vest Therapy Und, (Bo0) Hosp Vent Devices |
| Boston Scientific Corporation | $34.59 | 2025 | Enhance Transcarotid Peripheral Access Kit |
| Octapharma USA, INC. | $29.25 | 2023 | Octagam Immune Globulin (Human) |
| Allergan, INC. | $28.86 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.41 | 2023 | Hyqvia |
| Cormedix INC. | $25.21 | 2025 | Defencath |
| Pfizer INC. | $14.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Bhayani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.